Probiotic-based Antiviral Solutions for Specialized Applications
Legal Citation
Summary of the Inventive Concept
The present inventive concept discloses probiotic-based antiviral compositions and methods adapted for high-security biodefense, disaster relief, extreme weather conditions, and protecting high-risk populations from viral outbreaks.
Background and Problem Solved
The original patent disclosed antiviral methods and compositions comprising probiotic bacterial molecules for controlling pathogenic viruses in mammals. However, the patent's scope is limited to general antiviral applications. The present inventive concept addresses the need for specialized variations and niche solutions, focusing on high-consequence pathogens, disaster relief, extreme weather conditions, and high-risk populations.
Detailed Description of the Inventive Concept
The inventive concept comprises probiotic-based antiviral compositions and methods tailored to specific, narrow markets or unique operational environments. For high-security biodefense applications, the composition is formulated to be effective against a specific set of high-consequence pathogens. For disaster relief, the composition is packaged in a portable, easy-to-use format for administering to individuals in disaster-stricken areas. The portable antiviral kit for extreme weather conditions includes a probiotic-based antiviral composition, a water purification system, and a cold-chain storage unit. The system for protecting high-risk populations from viral outbreaks comprises a probiotic-based antiviral composition, a surveillance system for monitoring viral spread, and a communication network for rapid response. The method for protecting individuals in high-security environments from viral threats involves administering the antiviral composition, monitoring vital signs, and providing real-time feedback on immune system response.
Novelty and Inventive Step
The present inventive concept's novelty lies in its adaptation of probiotic-based antiviral compositions and methods to specific, high-stakes applications, addressing the limitations of the original patent. The inventive step is in the tailored formulations, packaging, and system integrations that enable effective antiviral protection in these unique environments.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include variations in probiotic strains, composition formulations, and system integrations to address specific pathogens, environments, or user needs. For example, the antiviral composition could be adapted for use in veterinary medicine or integrated into wearable devices for real-time monitoring.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the biodefense, disaster relief, and healthcare industries. The market for specialized antiviral solutions is substantial, driven by growing concerns about pandemic preparedness, bioterrorism, and extreme weather events. The inventive concept's adaptability to various applications and environments ensures broad market appeal.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Microbiology, immunology, and probiotic-based antiviral therapeutics, with expertise in bacterial strain selection, molecular characterization of probiotic secretions, and medical applications of microbial compositions
Person of Ordinary Skill (PHOSITA) Profile
A researcher or practitioner with advanced training in microbiology, immunology, and pharmaceutical development, capable of understanding probiotic strain characteristics, viral interaction mechanisms, and adaptive formulation strategies
Obviousness Rationale
A PHOSITA would recognize that the source patent's foundational probiotic antiviral methodology provides a clear technical framework for extending application to specialized environments. The PTD's variations represent predictable adaptations of known probiotic antiviral principles to specific use cases. The core scientific mechanism of probiotic-derived viral inhibition remains consistent across the disclosed embodiments, with the primary innovation being contextual implementation rather than fundamental scientific breakthrough.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,581 |
|---|---|
| Title | Antiviral methods and compositions comprising probiotic bacterial molecules |
| Assignee(s) | MICROSINTESIS INC. |